Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Cost of Revenue
Bioporto A/S
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bioporto A/S
CSE:BIOPOR
|
Cost of Revenue
-kr10.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
Genmab A/S
CSE:GMAB
|
Cost of Revenue
-kr411m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cost of Revenue
-kr23.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cost of Revenue
-€47.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cost of Revenue
-kr2.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-18%
|
Saniona AB
STO:SANION
|
Cost of Revenue
-kr52.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is Bioporto A/S's Cost of Revenue?
Cost of Revenue
-10.3m
DKK
Based on the financial report for Mar 31, 2024, Bioporto A/S's Cost of Revenue amounts to -10.3m DKK.
What is Bioporto A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was -2%.